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Abstract 
Background: While efficacy data exist, there are limited data on the outcomes of patients on third‑line antiretroviral 
therapy (ART) in sub‑Saharan Africa in actual practice. Being able to identify predictors of switch to third‑line ART will 
be essential for planning for future need. We identify predictors of switch to third‑line ART among patients with sig‑
nificant viraemia on a protease inhibitor (PI)‑based second‑line ART regimen. Additionally, we describe characteristics 
of all patients on third‑line at a large public sector HIV clinic and present their early outcomes.
Methods: Retrospective analysis of adults (≥ 18 years) on a PI‑based second‑line ART regimen at Themba Lethu 
Clinic, Johannesburg, South Africa as of 01 August 2012, when third‑line treatment became available in South Africa, 
with significant viraemia on second‑line ART (defined as at least one viral load ≥ 1000 copies/mL on second‑line ART 
after 01 August 2012) to identify predictors of switch to third‑line (determined by genotype resistance testing). Third‑
line ART was defined as a regimen containing etravirine, raltegravir or ritonavir boosted darunavir, between August 
2012 and January 2016. To assess predictors of switch to third‑line ART we used Cox proportional hazards regression 
among those with significant viraemia on second‑line ART after 01 August 2012. Then among all patients on third‑line 
ART we describe viral load suppression, defined as a viral load < 400 copies/mL, after starting third‑line ART.
Results: Among 719 patients in care and on second‑line ART as of August 2012 (with at least one viral load 
≥ 1000 copies/mL after 01 August 2012), 36 (5.0% over a median time of 54 months) switched to third‑line. Time on 
second‑line therapy (≥ 96 vs. < 96 weeks) (adjusted Hazard Ratio (aHR): 2.53 95% CI 1.03–6.22) and never reaching 
virologic suppression while on second‑line ART (aHR: 3.37 95% CI 1.47–7.73) were identified as predictors of switch. In 
a separate cohort of patients on third‑line ART, 78.3% (47/60) and 83.3% (35/42) of those in care and with a viral load 
suppressed their viral load at 6 and 12 months, respectively.
Conclusions: Our results show that the need for third‑line is low (5%), but that patients’ who switch to third‑line ART 
have good early treatment outcomes and are able to suppress their viral load. Adherence counselling and resistance 
testing should be prioritized for patients that are at risk of failure, in particular those who never suppress on second‑
line and those who have been on PI‑based regimen for extended periods.
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Background
In many resource-limited settings (RLS), antiretroviral 
therapy (ART) treatment guidelines call for switching 
patients who fail non-nucleoside reverse transcriptase 
inhibitor (NNRTI)-based first-line regimens to protease-
inhibitor (PI) based second-line regimens [1, 2]. Esti-
mates from sub-Saharan Africa in particular suggest that 
6% of all patients receiving first-line ART will require sec-
ond-line treatment per year [3]. However, when looking 
specifically at South Africa, this is estimated to be closer 
to 10% [4].
While the availability of second-line ART is expanding 
in RLS, only a few countries in these settings have treat-
ment options for patients who fail both NNRTI and PI-
based first and second-line therapies respectively [4]. Yet 
as treatment programs mature, an increasing number of 
patients are now failing second-line therapy [5, 6] forcing 
programs to make difficult decisions around whether or 
not to provide expensive third-line regimens. While the 
absolute number of patients failing second-line may be 
low, rates of second-line failure have been demonstrated 
to be as high as 38% by 36 months [7], a number that is 
likely an underestimate as limited viral load monitoring 
and genotyping has potentially led to under-reporting of 
treatment failure [8].
Since 2009 the World Health Organization (WHO) has 
recommended that third-line regimens be made available 
in all countries [9], however few are able to provide these 
regimens due to the high cost and complexity of imple-
mentation [6]. Third-line regimens include drugs such as 
newer generation NNRTIs like etravirine (ETV), boosted 
PIs like ritonavir boosted darunavir (DRV/r), as well as 
the integrase inhibitor raltegravir (RAL) [10]. Third-line 
ART has been estimated to be fifteen times more expen-
sive than first-line and six times more expensive than sec-
ond-line ART at current prices [11]. Current approaches 
to third-line therapy also require access to routine viral 
load monitoring and HIV resistance testing. Unlike the 
implementation of standardized first- and second-line 
regimens currently in use in most countries, third-line 
regimens are generally individualized to account for 
treatment history, toxicities as well as resistance pat-
terns and therefore require a higher cadre of health care 
workers.
South Africa is one of the few countries in sub-Saha-
ran Africa that has access to both resistance testing for 
patients failing second-line, as well as third-line drugs 
such as ETV, DRV/r and RAL in the public sector. As 
such we sought to use data from one of the largest 
cohorts of patients on second-line treatment in sub-Saha-
ran Africa that also had access to third-line. This enabled 
us to identify predictors of switching to third-line ART 
among those with significant viraemia on second-line 
therapy as well as describe early outcomes of patients on 
third-line ART.
Methods
Study site
We conducted a retrospective cohort study among adults 
(≥ 18  years) attending Themba Lethu Clinic in Johan-
nesburg, South Africa. The Themba Lethu Clinic cohort, 
which has been described in detail elsewhere [12, 13], 
is an urban public-sector HIV treatment site, and fol-
lows the South African National Department of Health 
(NDoH) adult ART treatment guidelines [14–17] (sum-
marized in Table 1). Since the start of the national pro-
gram in April 2004, more than 50,000 adults have been 
part of the Themba Lethu cohort, of whom close to 
40,000 have started on first-line and over 3000 on second-
line ART. In August 2012, Themba Lethu Clinic received 
access to third-line drugs and resistance testing through 
donor funding. Later, in 2013, access to resistance testing 
and third-line ART became available in the public sector.
South Africa uses HIV viral load testing to determine 
when a patient is considered to have failed an ART regi-
men. First-line treatment failure, defined as virologic 
failure, is defined as persistent viral loads ≥ 1000 copies/
mL on two occasions within a 3 month interval [17–19]. 
Given low rates of primary NNRTI resistance in South 
Africa which are estimated to be less than 5% [20], lack 
of viral suppression after treatment initiation is gener-
ally related to poor adherence. In order to delay switching 
to more expensive regimens, patients with an elevated 
viral load (≥ 1000  copies/mL) receive intensified adher-
ence counselling before repeating the viral load between 
1 and 3 months later. If patients fail to suppress they are 
then switched to a PI-based second-line regimen with the 
drug lopinavir/ritonavir (LPV/r).
The management of patients failing second-line 
ART using intensified adherence counselling has been 
described before [21, 22]. Briefly, at Themba Lethu Clinic 
patients with elevated viral loads on second-line receive 
intensified adherence counselling followed by repeat viral 
load monitoring 2–4  months later. Patients who resup-
press (< 400 copies/mL) continue to receive the standard 
of care. If they do not, patients are referred for ongoing 
adherence support. If the clinician decides adherence has 
improved and the viral load remains ≥ 1000 copies/mL 
or if resuppression is delayed (< 1 log reduction in viral 
load), resistance testing may be ordered [22]. Results of 
genotype tests, medical and social histories are reviewed 
and patients with PI resistance are recommended for 
third-line ART with an individualized regimen contain-
ing ETV, DRV/r and/or RAL. Third-line drugs are man-
aged centrally by the NDoH through application to a 
national third-line committee and decisions to allow use 
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are based on prior exposure, adherence and genotype 
results. Currently access to third-line drugs is limited to 
patients with PI-resistance.
At Themba Lethu Clinic, longitudinal clinical and 
demographic data are collected and stored on the elec-
tronic patient management system, TherapyEdge-HIV™. 
CD4 cell counts and viral load results are imported 
directly into the database from the National Health Lab-
oratory Service (NHLS) each day. Death is ascertained 
through patient tracing and is often reported or con-
firmed by family. Where available (61%), patients national 
identification numbers are linked with the National Vital 
Registration System to confirm all-cause mortality/death 
[23, 24].
Study population
As the study had two main objectives we analysed data 
from two overlapping study cohorts.
Second‑line cohort (predictors of switch to third‑line)
To predict switch to third-line we included adult 
(≥ 18 years at the availability of third-line) patients who 
were on a PI-based second-line regimen as of 01 August 
2012 at Themba Lethu Clinic. The analysis was restricted 
to patients with significant viraemia on second-line ART; 
those who had at least one viral load recorded at least 
3  months after commencing second-line ART and had 
a viral load ≥ 1000 copies/mL on at least one occasion 
after the availability of third-line ART (01 August 2012) 
[25–27].
Study variables
Current age, second-line regimen, viral load and CD4 
count are defined as the value closest to 01 August 2012. 
Initiating second-line regimen was defined as the first 
PI-based regimen after April 2004 but before 01 August 
2012. Time on second-line ART, calculated from start 
of second-line until 01 August 2012, was categorized at 
96  weeks based on standardized reporting of outcomes 
at 0, 24, 48 and 96  weeks. History of Tuberculosis (TB) 
treatment was defined as a TB diagnosis recorded in the 
clinical conditions or the prescription of anti-TB medica-
tion (e.g.  Rifafour® or any of the standard first-line agents 
used in the treatment of TB; rifampicin, isoniazid, pyrazi-
namide, streptomycin, ethambutol etc.) after the start 
of second-line ART but before 01 August 2012. Current 
TB treatment was defined as a TB diagnosis recorded or 
the prescription of anti-TB medication after the start of 
second-line ART and is still being administered as of 01 
August 2012.
Statistical analysis
The primary outcome of interest among those with sig-
nificant viraemia on second-line ART post 01 August 
2012 was switch to third-line ART. For the second-line 
cohort, demographic and clinical characteristics are pre-
sented using proportions for categorical variables and 
medians with corresponding interquartile ranges (IQR) 
for continuous variables.
We considered the following viral load responses 
as potential predictors of switch to third-line ART: (i) 
never suppressed on second-line (defined as all viral load 
results ≥ 400 copies/mL between 3 months post second-
line ART initiation and 01 August 2012); and (ii) viral 
load blips on second-line ART (0 vs. ≥ 1) (defined a viral 
load ≥ 1000 copies/mL preceded and followed by a viral 
load < 400  copies/mL; and restricted to patients with at 
least 3 viral loads between 3  months post second-line 
ART initiation and 01 August 2012). Additionally, we 
considered other potential predictors of switch to third-
line ART such as regimen change, defined as any change 
in regimen from the patients’ initiating second-line regi-
men before 01 August 2012.
To assess predictors of switch to third-line ART we 
used Cox proportional hazards regression among those 
with significant viraemia on second-line ART post 01 
August 2012. Follow-up time was calculated from 01 
August 2012 (the availability of third-line ART), until 
the earliest of switch to third-line, death, loss to fol-
low-up (LTF), transfer-out or close of dataset on 19 
January 2017. Loss to follow-up was defined as being 
≥ 3 months late for the last scheduled visit with no sub-
sequent visit. Variables with a p value less than 0.1 in 
the univariate analysis and a priori variables (e.g. age 
and gender) were included in the final multivariate 
model. Because the number with the outcome of inter-
est was limited (n = 36), the final model was restricted 
by the number of independent variables that could be 
added (i.e. one independent variable for every five to 
ten outcomes observed). All analyses were conducted 
using SAS version 9.3 (SAS Institute, Cary, North Car-
olina, USA).
Third‑line cohort
To describe characteristics of patients on third-line ART 
as well as their virologic outcomes, we included all adult 
patients (≥ 18  years at the availability of third-line; on 
third-line ART at Themba Lethu Clinic, defined as a regi-
men containing etravirine, ritonavir boosted darunavir or 
raltegravir between 01 August 2012 and 19 January 2016, 
allowing at least 12 months follow-up time for virologic 
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response (i.e. close of dataset 19 January 2017). Medical 
file reviews were used to confirm the start date of third-
line treatment. Clinical trial patients who transferred into 
Themba Lethu Clinic on a regimen containing one of 
the third-line drugs (e.g. ETV, DRV/r and RAL; n = 15) 
were excluded if available data confirmed that the clinical 
trial was not a third-line clinical trial (e.g. ACTG A5273, 
MK0518-292-00 and ACTG A5290).
Study variables
For the third-line cohort CD4 count and viral load clos-
est to the start of third-line ART were defined as a CD4 
count and viral load result after 01 August 2012, but no 
more than 14 days post third-line initiation to allow for 
laboratory reporting and capturing when manual data 
entry was required. We categorized third-line patients 
into: (1) those that had initiated third-line ART at 
Themba Lethu (those who were switched to third-line 
ART via following national treatment guidelines); and 
(2) those that had been transferred into Themba Lethu 
Clinic on a third-line regimen (i.e. because they had ini-
tiated third-line elsewhere, possibly as a clinical trial 
patient, and transferred into the clinic on third-line). We 
also report the proportion of patients that started third-
line in a clinical trial.
The primary outcome for the third-line cohort was viral 
load suppression on third-line ART; defined as a viral 
load < 400 copies/mL closest to 12 months post third-line 
initiation (± 3 months). We also estimate the proportion 
of patients virally suppressed (< 400  copies/mL) at the 
first follow-up viral load recorded, taken > 1  month but 
≤ 6  months after the start of third-line ART (early sup-
pression). Additionally, time to first ever suppressed viral 
load on third-line ART was defined as the time in months 
from 1  month post third-line ART initiation to first 
ever suppressed viral load (< 400  copies/mL) recorded 
within the 12 (± 3) months of follow-up from third-line 
initiation.
Statistical analysis
For the third-line cohort, we again present demographic 
and clinical characteristics using proportions for categor-
ical variables and medians with corresponding IQRs for 
continuous variables.
For patients who transferred-out to another facility 
after start of third-line ART, we reviewed the patient 
clinic file and recorded the transfer-out facility. Where 
possible, we traced patients (using their unique patient 
identification number on TherapyEdge-HIV™) to the 
transfer facility and recorded viral load results that 
were available. This allowed us to assign a viral load 
outcome to patients that were previously reported as 
transfer-out.
Results
Cohort descriptions
Among 719 patients in care, on second-line ART at 
Themba Lethu Clinic with significant viraemia after 
01 August 2012, more than two-thirds were female 
(66.8%; 480/719) with a median age of 39.4  years (IQR 
33.3–46.3). Most patients initiated on a second-line regi-
men of TDF, 3TC/FTC and LPVr (27.3%; 196/719), fol-
lowed by zidovudine (AZT), AZT, 3TC/FTC and LPVr 
(22.7%; 163/719) and then AZT, LPVr and didanosine 
(ddI) (16.6%; 119/719) (Table 2). At start of follow-up (01 
August 2012), the median (IQR) CD4 count was 415.0 
(253.0–583.0) and the median (IQR) viral load was 249.5 
(51.0–2791.5) copies/mL (Table 2).
Among 719 patients with significant viraemia on sec-
ond-line ART after 01 August 2012, 36/719 (5.0% over a 
median time of 54  months) switched to third-line ART. 
When looking at poor viral load response during second-
line ART, a higher proportion of patients who switched 
to third-line (n = 36) experienced viral load blips on sec-
ond-line ART (46.7% vs. 34.3%) or never suppressed on 
second-line ART (27.3% vs. 14.4%).
Predictors of switch to third‑line ART
While no differences were observed across gender, age 
groups and regimen change, we found that time on sec-
ond-line prior to the availability of third-line ART, calcu-
lated from start of second-line until 01 August 2012, was 
a strong predictor of switch among those with significant 
viraemia (≥ 96  weeks vs. < 96; aHR 2.53 95% CI 1.03–
6.22). When considering indicators of poor viral load 
response patients who never managed to suppress their 
viral load while on second-line therapy were more likely 
to switch to third-line ART (aHR 3.37 95% CI 1.47–7.73) 
(Table 3).
Characteristics of patients on third‑line ART at Themba 
Lethu Clinic
Table  4 presents the characteristics and early outcomes 
of patients on third-line ART. From 01 August 2012 to 19 
January 2016, 82 patients received third-line ART treat-
ment at Themba Lethu Clinic. Just over half of them 
(63.4%, 52/82) initiated a third-line regimen containing 
ritonavir boosted darunavir—alone or in combination 
with raltegravir or etravirine. Close to half (42.7%; 35/82) 
had a regimen containing raltegravir, alone or in combi-
nation with other drugs. Half of patients (50.0%) had a 
regimen containing four or more drugs and 24.4% had a 
regimen containing five or more drugs. 43.9% (36/82) had 
a TDF or TDF and AZT NRTI backbone.
Of those on third-line, 37.8% were male (n = 31) and 
the median age at third-line initiation was 40.0 years (IQR 
35.5–47.3). At third-line ART initiation, the CD4 count 
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was 277.0 cells/mm3 (IQR 194.0–439.0) and median viral 
load was 13,930.0 copies/mL (IQR 2655.0–62,515.0).
Patients on third-line ART who were referred into 
Themba Lethu Clinic (n = 46) were similar to those that 
initiated second-line ART and switched to third-line 
ART at Themba Lethu Clinic in terms of the character-
istics described in Table  4, aside from a high propor-
tion of male patients (41.3 vs. 33.3%), lower proportion 
Table 2 Characteristics of patients included in the second-line cohort (n = 719)
ABC abacavir; 3TC lamivudine; FTC emtricitabine; LPVr lopinavir ritonavir; TDF tenofovir; AZT zidovudine; ddI didanosine; d4T stavudine, IQR interquartile range
Characteristic at second‑line initiation Total
(n = 719)
Switched to third‑line
(n = 36)
Patients remaining on second‑line
(n = 683)
Gender N, %
 Male 239/719 (33.2%) 12/36 (33.3%) 227/683 (33.2%)
 Female 480/719 (66.8%) 24/36 (66.7%) 456/683 (66.8%)
Current age, years Median, IQR 39.4 (33.3‑46.3) 40.0 (35.2‑46.8) 39.3 (33.3–46.3)
 < 30 N, % 92/719 (12.8%) 4/36 (11.1%) 88/683 (12.9%)
 30–45 417/719 (58.0%) 20/36 (55.6%) 397/683 (58.1%)
 ≥ 45 210/719 (29.2%) 12/36 (33.3%) 198/683 (29.0%)
Current CD4 count, cells/mm3 Median, IQR 415.0 (253.0‑583.0) 298.5 (183.0‑397.0) 420.5 (255.0–592.0)
 < 100 N, % 49/600 (8.2%) 4/26 (15.4%) 45/574 (7.8%)
 100–200 61/600 (10.2%) 3/26 (11.5%) 58/574 (10.1%)
 200–350 131/600 (21.8%) 8/26 (30.8%) 123/574 (21.4%)
 ≥ 350 359/600 (59.8%) 11/26 (42.3%) 348/574 (60.6%)
 Missing 119 10 109
Current second‑line regimen N, %
 AZT + ddI + LPVr 7/719 (1.0%) 1/36 (2.8%) 6/683 (0.9%)
 TDF + 3TC/FTC + LPVr 247/719 (34.4%) 10/36 (27.8%) 237/683 (34.7%)
 AZT + 3TC + LPVr 259/719 (36.0%) 16/36 (44.4%) 243/683 (35.6%)
 Other 206/719 (28.7%) 9/36 (25.0%) 197/683 (28.8%)
Current viral load, copies/mL Median, IQR 249.5 (51.0‑2791.5) 6510.0 (1505.0‑32,718.0) 235.0 (49.0–1932.0)
 < 1000 N, % 453/660 (68.6%) 8/33 (24.2%) 445/627 (71.0%)
 1000–50,000 140/660 (21.2%) 19/33 (57.6%) 121/627 (19.3%)
 ≥ 50,000 67/660 (10.2%) 6/33 (18.2%) 61/627 (9.7%)
 Missing 59 3 56
Year of second‑line initiation N, %
 2004–2010 313/719 (43.5%) 22/36 (61.1%) 291/683 (42.6%)
 2010–2012 406/729 (56.5%) 14/36 (38.9%) 392/683 (57.4%)
Initiating second‑line regimen N, %
 AZT + ddI + LPVr 119/719 (16.6%) 10/36 (27.8%) 109/683 (16.0%)
 TDF + 3TC/FTC + LPVr 196/719 (27.3%) 6/36 (16.7%) 190/683 (27.8%)
 AZT + 3TC + LPVr 163/719 (22.7%) 6/36 (16.7%) 157/683 (23.0%)
 Other 241/719 (33.5%) 14/36 (38.9%) 227/683 (33.2%)
Never suppressed on second‑line ART prior to 
August 2012
N, % 90/595 (15.1%) 9/33 (27.3%) 81/562 (14.4%)
 Missing 124 3 121
Viral load blips on second‑line prior to August 
2012
N, %
 0 317/488 (65.0%) 16/30 (53.3%) 301/458 (65.7%)
 ≥ 1 171/488 (35.0%) 14/30 (46.7%) 157/458 (34.3%)
 Missing 231 6 225
Time to first viral load on second‑line ART, days Median, IQR 175.0 (125.0–252.0) 169.0 (118.0–280.0) 175.0 (126.0–244.0)
Total person time calculated from 01 August 2012, 
months
Median, IQR 53.5 (44.7–53.5) 12.4 (8.0–25.3) 53.5 (51.9–53.5)
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of patients aged 18–30 years (2.2 vs. 11.1%), higher pro-
portion of patients with CD4 cell counts ≥ 350 cells/
mm3 (48.4 vs. 25.9%), lower median viral load (7883.0 
vs. 24,096.5  copies/mL) around the first recorded date 
of third-line ART as well as year starting third-line ART 
(2012; 37.0 vs. 8.3%, 2013–2016; 63.0 vs. 91.7%). Of the 
46 patients identified to be referrals to third-line ther-
apy (i.e. transferred into Themba Lethu Clinic on third-
line), 10 (21.7%) had initiated treatment in a clinical trial 
(Additional file 1: Table S1).
At the end of follow-up the majority of patients were 
alive, in care (87.8%, n = 72/82) while 6.1% had trans-
ferred out (n = 5/82), 1.2% were loss to follow-up 
(n = 1/82) and 4.9% had died (n = 4/82) (Table  4). Of 
those that transferred out, tracing initiatives yielded 
viral load results for 4 of the 5 patients, with 4 patients 
(80%; 4/5) achieving viral suppression within 12 months 
of starting third-line. Of all patients in care and on third-
line ART, 61.0% (47/77) and 48.6% (35/72) suppressed 
their viral load at 6 and 12 months, respectively. By trac-
ing patients that transferred out (n = 5), this increased to 
50.7% (39/77) by the end of follow-up. However, among 
all patients in care and on third-line ART with a viral load 
measured at 6 and 12 months, 78.3% (47/60) and 83.3% 
(35/42) suppressed their viral load respectively.
Among the 36 patients that initiated third-line ART at 
Themba Lethu, 44.4% (95% CI 29.0–60.8%) were virally 
suppressed (n = 16/36) by 12 months after third-line ART 
initiation. This was higher than the 41.3% (95% CI 27.8–
55.9%) suppression among referral patients (n = 19/46).
Table 3 Crude and adjusted hazard ratios of switch to third-line (n = 719)
ABC abacavir, 3TC lamivudine, FTC emtricitabine, LPVr lopinavir/ritonavir, TDF tenofovir, AZT zidovudine, ddI didanosine, d4T stavudine, HR hazard ratio, aHR adjusted 
hazard ratio; * p < 0.05
Characteristics at second‑line initiation N, row % Crude HR 95% CI P value aHR 95% CI P value
Gender
 Female 24/480 (5.0%) 1.0 1.0
 Male 12/239 (5.0%) 1.01 (0.50–2.01) 0.99 1.09 (0.52–2.29) 0.81
Age, years
 18–30 8/156 (5.1%) 1.0 1.0
 30–45 20/407 (4.9%) 0.95 (0.42–2.15) 0.90 0.91 (0.39–2.11) 0.82
 ≥ 45 8/156 (5.1%) 0.95 (0.36–2.54) 0.93 0.89 (0.32–2.49) 0.82
Time on second‑line (calculated from start of second‑line until 01 August 2012), weeks
 < 96 9/317 (2.8%) 1.0 1.0
 ≥ 96 27/402 (6.7%) 2.37 (1.11–5.03) 0.03* 2.53 (1.03–6.22) 0.04*
Regimen change prior to 01 August 2012
 No 20/493 (4.1%) 1.0
 Yes 16/226 (7.1%) 1.76 (0.91–3.39) 0.09
Current CD4 count, cells/mm3
 < 100 4/49 (8.2%) 2.81 (0.90–8.83) 0.08
 100–200 3/61 (4.9%) 1.66 (0.46–5.96) 0.43
 200–350 8/131 (6.1%) 2.10 (0.85–5.23) 0.11
 ≥ 350 11/359 (3.1%) 1.0
Never suppressed on second‑line ART prior to August 2012
 No 24/505 (4.8%) 1.0 1.0
 Yes 9/90 (10.0%) 2.32 (1.08–4.99) 0.03* 3.37 (1.47–7.73) 0.00*
Viral load blips on second‑line ART prior to August 2012
 0 16/317 (5.1%) 1.0
 ≥ 1 14/171 (8.2%) 1.64 (0.80–3.36) 0.18
History of TB
 No 30/658 (4.6%) 1.0 1.0
 Yes 6/61 (9.8%) 2.29 (0.95–5.50) 0.06 1.99 (0.81–4.85) 0.13
Currently on TB treatment
 No 34/694 (4.9%) 1.0
 Yes 2/25 (8.0%) 1.75 (0.42–7.27) 0.44
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Table 4 Third-line regimen patient characteristics and early outcomes on third-line ART
Characteristic at start of third‑line Total
(n = 82)
Switched to third‑line
(n = 36)
Transferred in on third‑line ART
(n = 46)
Gender N, %
 Male 31/82 (37.8%) 12/36 (33.3%) 19/46 (41.3%)
 Female 51/82 (62.2%) 24/36 (66.7%) 27/46 (58.7%)
Age, years Median, IQR 40.0 (35.5–47.3) 40.0 (35.2–46.8) 40.0 (36.2–47.3)
 18–30 N, % 5/82 (6.1%) 4/36 (11.1%) 1/82 (2.2%)
 30–45 52/82 (63.4%) 20/36 (55.6%) 32/82 (69.6%)
 ≥ 45 25/82 (30.5%) 12/36 (33.3%) 13/82 (28.3%)
CD4 count closest to start of third‑line ART, 
cells/mm3
Median, IQR
N, %
277.0 (194.0–439.0) 263.0 (156.0–390.0) 339.0 (212.0–472.0)
 < 100 9/58 (15.5%) 5/27 (18.5%) 4/31 (12.9%)
 100–200 6/58 (13.7%) 3/27 (11.1%) 3/31 (9.7%)
 200–350 21/58 (32.9%) 12/27 (44.4%) 9/31 (29.0%)
 ≥ 350 22/58 (35.6%) 7/27 (25.9%) 15/31 (48.4%)
 Missing 24/82 9/36 15/46
Third‑line regimen N, %
 DRV/r + RAL + ETV 0/82 (0.0%) 0/36 (0.0%) 0/46 (0.0%)
 DRV/r + RAL 17/82 (20.7%) 11/36 (30.6%) 6/46 (13.0%)
 RAL + ETV 0/82 (0.0%) 0/36 (0.0%) 0/46 (0.0%)
 DRV/r + ETV 5/82 (6.1%) 2/36 (5.6%) 3/46 (6.5%)
 DRV/r 30/82 (36.6%) 12/36 (33.3%) 18/46 (39.1%)
 RAL 18/82 (22.0%) 4/36 (11.1%) 14/46 (30.4%)
 ETV 12/82 (14.6%) 7/36 (19.4%) 5/46 (10.9%)
NRTI backbone
 TDF 31/82 (37.8%) 13/36 (36.1%) 18/46 (39.1%)
 AZT 4/82 (4.9%) 1/36 (2.8%) 3/46 (6.5%)
 ABC 0/82 (0.0%) 0/36 (0.0%) 0/46 (0.0%)
 TDF + AZT 5/82 (6.1%) 4/36 (11.1%) 1/46 (2.2%)
 TDF + ABC 0/82 (0.0%) 0/36 (0.0%) 0/46 (0.0%)
 Other 42/82 (51.2%) 18/36 (50.0%) 24/46 (52.2%)
Viral load closest to start of third‑line ART, 
copies/mL (> 400 copies/mL)
Median, IQR
N, %
13,930.0 (2655.0–62,515.0) 24,096.5 (3877.5–84,934.0) 7883.0 (1504.0–41,485.0)
 < 1000 11/73 (15.1%) 3/36 (8.3%) 8/37 (21.6%)
 1000–50,000 40/73 (54.8%) 20/36 (55.6%) 20/37 (54.1%)
 ≥ 50,000 22/73 (30.1%) 13/36 (36.1%) 9/37 (24.3%)
 Missing 9/82 0/36 9/46
Year starting third‑line ART N, %
 2012 20/82 (24.4%) 3/36 (8.3%) 17/46 (37.0%)
 2013–2016 62/82 (75.6%) 33/36 (91.7%) 29/46 (63.0%)
Time to first ever viral suppression on 
third‑line
N, %
 1–6 months 49/82 (59.8%) 22/36 (61.1%) 27/46 (58.7%)
 6–12 months 16/82 (19.5%) 7/36 (19.4%) 9/46 (19.6%)
 Missing 17/82 (20.7%) 7/36 (19.4%) 10/61 (21.7%)
Outcomes on third‑line ART
 Viral suppression on third‑line by first viral 
load within 6 months (early suppres‑
sion)
N, %
  Alive, in care and suppressed 47/82 (57.3%) 20/36 (55.6%) 27/46 (58.7%)
  Alive, in care and not suppressed 13/82 (15.9%) 7/36 (19.4%) 6/46 (13.0%)
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Discussion
As ART programmes in sub-Saharan Africa mature, 
increasing numbers of people will require third-line 
regimens. Here we report that 5% of patients with sig-
nificant viraemia on second-line ART at Themba Lethu 
Clinic switched to third-line ART (over a median time of 
54 months). The small proportion in need of third-line is 
consistent with what has been previously reported [6].
Implementation of third-line ART is resource intensive 
and requires more expensive drugs, access to resistance 
testing and an individualized approach to therapy where 
drug history, treatment toxicities and resistance patterns 
of patients are all taken into account. In a recent study 
of 400 patients with significant viraemia on second-line 
(viral load ≥ 1000  copies/mL) at Themba Lethu, the 
majority (65%) were able to re-suppress their viral load 
within 6  months following an adherence intervention 
while only 6% required third-line ART [22, 28]. Studies 
have shown the benefits of intensive adherence coun-
selling among patients failing second-line ART, with 
patients re-suppressing following intensive counselling 
and adherence support, subsequently avoiding switching 
to more expensive third-line regimens [29].
A high HIV RNA at baseline or start of second-line 
ART has been demonstrated by others as a strong inde-
pendent predictor of second-line failure [30–33]. In 
addition to a high burden of virus at the start of sec-
ond-line ART, here we report that patients who never 
reach virologic suppression while on second-line are at 
increased risk of switch to third-line (aHR 3.37 95% CI 
1.47–7.73). We also report that patients on second-line 
ART ≥ 96 weeks to be two and half time more likely to 
switch to third-line therapy (aHR 2.53 95% CI 1.03–6.22). 
Contrary to other reports we did not find that patients 
on TB treatment or those with a history of TB treatment 
were at increased risk of treatment failure or switch [25]. 
Reports have shown that Rifampicin, the cornerstone of 
anti-TB therapy, can reduce the PI tough concentration 
by more than 90% [34, 35]. Even though TB treatment 
was not identified as a significant predictor in this study, 
it should be noted that TB treatment may be a significant 
clinical contributing factor, especially if the dose of rito-
navir is not adjusted to account for the reduced PI con-
centration associated with concomitant rifampicin [36].
Studies have demonstrated that patients who have 
suboptimal adherence to first-line ART are more likely 
to have suboptimal adherence to second-line ART and 
probably also third-line ART [37]. Therefore, these indi-
viduals should be targeted for interventions to improve 
adherence during first-line ART to avoid failure and 
switching to more expensive regimens in the future. Sub-
optimal adherence and drug resistance may all be con-
tributing to the increased risk of treatment failure and 
the need for third-line ART. A study conducted by Cox 
and colleagues among second-line ART patients with an 
elevated viral load of more than 400 copies/mL in a large 
ABC abacavir; 3TC lamivudine; LPVr lopinavir ritonavir; TDF tenofovir; AZT zidovudine; ddI didanosine; d4T stavudine, ETR etravirine, RAL raltegravir, DRV/r ritonavir 
boosted darunavir, IQR interquartile range
* Loss to follow-up defined as missing their last scheduled visit ≥ 3 months
Table 4 continued
Characteristic at start of third‑line Total
(n = 82)
Switched to third‑line
(n = 36)
Transferred in on third‑line ART
(n = 46)
  Alive, in care and no repeat viral load/no 
repeat viral load within follow‑up
17/82 (20.7%) 7/36 (19.4%) 10/46 (21.7%)
Not alive or in care
 Died 2/82 (2.4%) 1/36 (2.8%) 1/46 (2.2%)
 Loss to follow‑up* 0/82 (0.0%) 0/36 (0.0%) 0/46 (0.0%)
 Transfer‑out 3/82 (3.7%) 1/36 (2.8%) 2/46 (4.4%)
Viral suppression on third‑line by 
12 months
N, %
 Alive, in care and suppressed 35/82 (42.7%) 16/36 (44.4%) 19/46 (41.3%)
 Alive, in care and not suppressed 7/82 (8.5%) 5/36 (13.9%) 2/46 (4.4%)
 Alive, in care and no repeat viral load/no 
repeat viral load within follow‑up
30/82 (36.6%) 12/36 (33.3%) 18/46 (39.1%)
Not alive or in care
 Died 4/82 (4.9%) 2/36 (5.6%) 2/46 (4.4%)
 Loss to follow‑up* 1/82 (1.2%) 0/36 (0.0%) 1/46 (2.2%)
 Transfer‑out 5/82 (6.1%) 1/36 (2.8%) 4/46 (8.7%)
Never suppressed viral load below 400 cop‑
ies/mL by 12 months
N, % 6/71 (8.5%) 4/33 (12.1%) 2/38 (5.3%)
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informal settlement outside Cape Town in South Africa, 
suggests that patients who re-suppress at the first follow-
up viral load test are three times more likely to remain 
virally suppressed, compared to those who reach viral re-
suppression later (aHR 3.15 95% CI 2.2–4.4). The same 
may be true for viral suppression after starting second-
line ART, highlighting that the main focus for patients 
failing second-line should be on adherence support [38]. 
Our study did not include genotypic resistance data, but 
supports findings of other studies which have reported 
that poor adherence, rather than drug resistance, as a 
major determinant of virologic failure among patients on 
second-line ART [30].
Compared to those who remained on second-line and 
did not switch, we show that patients who switched to 
third-line had lower CD4 counts at the start of follow-up 
(01 August 2012) (< 100 cells/mm3; 15.4% vs. 7.8%). Others 
have also shown that lower CD4 count at start of second-
line predicts failure to achieve viral suppression on second-
line ART [39, 40]. While no discernible differences were 
observed across gender, some reports suggest females are 
generally at higher risk of failure and switch to third-line 
[6, 41], while findings from resource-limited settings report 
male gender to be associated with these outcomes [42–44]. 
In our setting however, the risk for significant viraemia and 
switch to third-line was similar for males and females.
Of all patients receiving third-line ART at Themba 
Lethu Clinic, we found 42.7% (35/82; 95% CI 32.3–
53.6%) suppressed their viral load on third-line ART by 
12 months (35/72; 48.6% 95% CI 37.2–60.1 among those 
alive and in care at 12 months and 35/42; 83.3% 95% CI 
69.8–92.4 among those alive and in care at 12  months 
with a viral load measured at this time). More spe-
cifically, majority of third-line patients (57.3% of all 
patients or 47/82; 61.0% among those alive and in care 
at 6 months and 47/60; 78.3% among those alive and in 
care at 6 months with a viral load measured at this time) 
achieved viral suppression in the first 6  months (early 
suppression). Time to first ever suppressed viral load 
while on third-line was relatively short with two-thirds 
of patients achieving their first ever suppressed viral load 
within 6  months of third-line initiation (59.8%). These 
results are consistent with those reported from Mumbai, 
India where most (61%; 11/18) patients achieved viro-
logic suppression after a median duration of 6  months 
(183 days) on third-line ART [26]. Virologic suppression 
< 400 copies/mL has been reported as high as 83% among 
patients on third-line ART in South Africa (n = 152), 
however the study was conducted among patients on 
salvage ART in a Southern African private sector disease 
management program [5].
Moderate to high rates of loss to follow up (1.2%) and 
transfer-out (6.1%) respectively, may have restricted 
repeat viral load testing and subsequently underesti-
mated suppression rates. To overcome this we managed 
to trace and obtain viral load outcomes for four of the 
five transfer-out patients. All four patients with viral load 
results were suppressed. For those patients with viral 
load data between 1 and 12 months of starting third-line 
(n = 71), 8.5% (95% CI 3.5–16.7; 6/71) never suppressed 
their viral load below 400 copies/mL.
This study has several limitations in addition to those 
already mentioned. We included patients on second-line 
ART as of 01 August 2012, when third-line became avail-
able, which may have introduced selection bias. Some 
potential predictors of treatment failure such as meas-
ures of adherence and routine resistance testing were not 
assessed in this study. However, the examination of more 
proximal determinants of significant viraemia (dura-
tion of current therapy and virologic response) may be 
important to evaluate, particularly in resource-limited 
settings where robust measures may not be readily avail-
able. Additionally, after March 2012 the standard of care 
for patients with an elevated viral load while on second-
line therapy has improved with more intensified adher-
ence counselling, follow-up and more frequent visits with 
experienced medical officers [28]. Our results may there-
fore not be generalizable to all public sector HIV clinics 
which rely on standard adherence counselling offered by 
a social worker/counsellor or may not have any resources 
devoted to adherence counselling. Although alive and in 
care post third-line ART initiation, 30/82 (36.6%) patients 
had no viral loads recorded, thus the proportion reported 
to be suppressed may be an underestimate due to miss-
ing data. We report that 22.0% of patients who received 
third-line contained a single third-line drug of RAL 
alone. This does not seem appropriate for a third-line 
regimen in patients with resistance to other agents and 
suggests that data may be incomplete. The limitations of 
routine data are well-described [45]. For transfer-in and 
transfer-out patients we could only trace these patients to 
the neighbouring HIV clinical trials unit, which also uses 
TherapyEdge-HIV™, where electronic medical records 
were linked using the unique patient identification 
number or TE number. Additionally, for patients who 
transferred in on a third-line regimen, treatment infor-
mation preceding the date of transfer such as participa-
tion in a clinical trial patient or time on third-line are not 
available.
Conclusion
Our results show that the need for third-line, based on 
significant viraemia while on second-line ART, is low 
(5% over a median time of 54 months). But that patients’ 
who switch to third-line ART have good early treat-
ment outcomes and are able to suppress their viral load. 
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Adherence counselling and resistance testing should be 
prioritized for patients that are at risk of failure, in par-
ticular those who never suppress on second-line and 
those who have been on PI-based regimen for extended 
periods. Despite a poor response to second-line ART, 
we report 57.3% (47/82) of all patients on third-line ART 
suppressed their viral load during the first 6  months 
on third-line therapy. In addition, tracing initiatives 
confirmed that 93.9% (77/82) of patients on third-line 
remained alive and in care by 12 months.
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